Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
A tumescent composition comprising a biologic drug in a tumescent solution, wherein a tumescent concentration of the biologic drug is simultaneously below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; and the tumescent solution comprises a vasoconstrictor; a pharmaceutically acceptable carrier; and optionally a local anesthetic.
1. A tumescent composition comprising a biologic drug in a tumescent solution, wherein
the tumescent solution comprises:
(i) a vasoconstrictor;
(ii) a pharmaceutically acceptable carrier; and
(iii) optionally a local anesthetic,
wherein the biologic drug is selected from the group consisting of an antibody that targets specific Cluster of Differentiation (CD) antigens or CD markers on malignant cells and a monoclonal antibody,
wherein the antibody or the monoclonal antibody does not bind to HER2 receptor, VEGF-A or CD20.
2. The tumescent composition of claim 1 , wherein said optional local anesthetic is lidocaine.
3. The tumescent composition of claim 2 , wherein the concentration of lidocaine is approximately 100 mg to 1,500 mg per L of solution.
4. The tumescent composition of claim 1 , wherein said tumescent composition further comprises an anti-inflammatory agent.
5. The tumescent composition of claim 1 , wherein said vasoconstrictor comprises epinephrine.
6. The tumescent composition of claim 5 wherein the concentration of epinephrine is approximately 0.2 to 1.5 mg/L.
7. The tumescent composition of claim 1 , wherein said tumescent composition further comprises an agent that reduces neuropathic pain or a risk of developing neuropathic pain.
8. A method of subcutaneous delivery of a drug or a therapeutic agent to a subject comprising administering to said subject the tumescent composition according to claim 1 .
9. The method of claim 8 , wherein infiltration of the tumescent composition achieves both prolonged local drug concentration within a tumescent subcutaneous tissue as well as a prolonged slow constant systemic absorption of drugs from the tumescent tissue into a systemic circulation.
10. The method of claim 8 , wherein a pharmacokinetic profile of the systemic absorption resembles a slow, constant, intravenous (IV) infusion.
11. The method of claim 8 , wherein the subcutaneous concentration of the drug or therapeutic agent achieved is from about 1-100 times the maximum subcutaneous interstitial fluid concentration that can be achieved by conventional IV, IM or oral delivery of the drug or therapeutic agent.
12. The method of claim 8 , wherein local and systemic blood viscosity are reduced in the subject and local and systemic oxygenation of tissues in the subject is increased.
13. The method of claim 8 , wherein said tumescent composition further comprises an agent that reduces neuropathic pain or the risk of developing neuropathic pain.
14. The method of claim 13 , wherein said neuropathic pain is selected from the group consisting of postherpetic neuralgia, trigeminal neuralgia, phantom limb pain, diabetic neuropathy, carpal tunnel syndrome, sciatica, degenerative disk disease, spinal cord injury, post-surgical pain and cancer.